Ceapro Inc (TSE:CZO) has released an update.
Aeterna Zentaris and Ceapro Inc. have received approval from their securityholders for a proposed all-stock merger, paving the way for the creation of a merged biopharmaceutical entity. The approval, which came through with a clear majority at special meetings, supports the companies’ vision of a sustainable business aimed at delivering value to the biopharma sector and its shareholders. The merger is expected to close in the second quarter of 2024, with the newly formed company to be renamed and listed on the Nasdaq and TSX.
For further insights into TSE:CZO stock, check out TipRanks’ Stock Analysis page.
